SCHEMBL6296402

SCHEMBL6296402

Cc1ccc(S(=O)(=O)Sc2cc(N)c(N)cc2C(C)(C)C)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DNMT1 P26358 1/20 0.47
BCHE P06276 4/20 0.40
ACHE P22303 4/20 0.40
G6PD P11413 3/20 0.38
FFAR4 Q5NUL3 1/20 0.37
CA12 O43570 1/20 0.37
CA1 P00915 1/20 0.37
CA2 P00918 1/20 0.37
CA3 P07451 1/20 0.37
CA6 P23280 1/20 0.37
CA5A P35218 1/20 0.37
CA7 P43166 1/20 0.37
CA9 Q16790 1/20 0.37
CA5B Q9Y2D0 1/20 0.37
TLR9 Q9NR96 1/20 0.36
GAA P10253 2/20 0.35
ALDH1A1 P00352 2/20 0.34
KMT2A Q03164 2/20 0.34
MEN1 O00255 1/20 0.34
IDE P14735 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5880835 0.92 DNMT1 (0.45) DNMT1BCHEACHEG6PDFFAR4
Hydrochloric Acid SCHEMBL5880769 0.90 DNMT1 (0.44) DNMT1BCHEACHEG6PDFFAR4
SCHEMBL8702569 0.81 DNMT1 (0.46) DNMT1BCHEACHEG6PDFFAR4
SCHEMBL8008611 0.80 DNMT1 (0.45) DNMT1BCHEACHEG6PDCA12
SCHEMBL5880909 0.79 DNMT1 (0.41) DNMT1BCHEACHEG6PDCA12
SCHEMBL6378684 0.78 KMT2A (0.44) DNMT1BCHEACHEG6PDGAA
SCHEMBL6302820 0.78 DNMT1 (0.43) DNMT1BCHEACHEG6PDALDH1A1
SCHEMBL5881069 0.78 ALDH1A1 (0.48) DNMT1CA2GAAALDH1A1KMT2A
SCHEMBL6302939 0.78 ALDH1A1 (0.48) DNMT1CA2GAAALDH1A1KMT2A
SCHEMBL8520618 0.77 DNMT1 (0.45) DNMT1BCHEACHEG6PDCA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050075390-A1 HIV protease inhibitors AGOURON PHARMACEUTICALS, INC. 2005-04-07 US disclosed
US-6852711-B2 Novel dihydropyrones with tethered heterocycles having improved pharmacologic properties which potently inhibit the HIV aspartyl protease blocking HIV infectivity. The dihydropyrones are useful in the development of therapies for AGOURON PHARMACEUTICALS, INC. (US) 2005-02-08 US disclosed
US-20040106606-A1 HIV protease inhibitors BOYER FREDERICK EARL (US) 2004-06-03 US disclosed
US-6528510-B1 Dihydropyrones with tethered heterocycles; 3-(2-tert-Butyl-4-hydroxymethyl-5-methyl-phenylsulfanyl)-4-hydroxy-6 -isopropyl-6-(2-pyridin-4-yl-ethyl)-5,6-dihydro-pyran - 2-one; WARNER-LAMBERT COMPANY 2003-03-04 US disclosed
EP-1112269-A2 HIV PROTEASE INHIBITORS WARNER-LAMBERT COMPANY (US) 2001-07-04 EP disclosed
WO-2000015634-A2 HIV PROTEASE INHIBITORS WARNER-LAMBERT COMPANY (US) 2000-03-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040106606-A1 HIV protease inhibitors DNPEP, PREP, PEPD DNMT1 3820/4885BCHE 1280/4885ACHE 2119/4885
US-20050075390-A1 HIV protease inhibitors DNPEP, PREP, PEPD DNMT1 3678/4885BCHE 1354/4885ACHE 2262/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.